|
1) Ishikawa F, Livingston AG, Wingard JR, et al. An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/beta2-microglobulin(null) mice. Exp Hematol. 2002; 30: 488-94
|
|
|
|
2) Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005; 106: 1565-73
|
|
|
|
|
|
3) Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nature Reviews Immunology. 2007; 7: 118-30
|
|
|
|
|
|
4) Ueda T, Tsuji K, Yoshino H, et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest. 2000; 105: 1013-21
|
|
|
|
|
|
5) McKenzie JL, Gan OI, Doedens M, et al. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122＋ cells. Blood. 2005; 106: 1259-61. Epub 2005 May 5
|
|
|
|
|
|
6) Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-8
|
|
|
|
|
|
7) Feuring-Buske M, Gerhard B, Cashman J, et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia. 2003; 17: 760-3
|
|
|
|
|
|
8) Ninomiya M, Abe A, Katsumi A, et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia. 2007; 21: 136-42
|
|
|
|
|
|
9) Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells−perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Research. 2006; 66: 9339-44
|
|
|
|
|
|
10) Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. Science. 2007; 317: 337
|
|
|
|
|
|
11) Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133＋ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest. 2008; 118: 2111-20
|
|
|
|
|
|
12) Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotechnology. 2007; 25: 1315-21
|
|
|
|
|
|
13) Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004; 118: 149-61
|
|
|
|
|
|
14) Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006; 25: 977-88
|
|
|
|
|
|
15) Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003; 425: 836-41
|
|
|
|
|
|
16) Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425: 841-6
|
|
|
|
|
|
17) Kiel MJ, Morrison SJ. Maintaining hematopoietic stem cells in the vascular niche. Immunity. 2006; 25: 862-4
|
|
|
|
|
|
18) Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell. 2007; 1: 204-17
|
|
|
|
|